Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Completed · Phase 2

Conditions studied: Melanoma

In brief

The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.

Key facts

Study ID

NCT01673854

Run by

Bristol-Myers Squibb

People needed

70

Starts

2012-09-13

Expected to finish

2015-05-12

Last updated by the study team

2018-07-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Beverly Hills Cancer Center — Beverly Hills, California, United States
• Baptist Cancer Institute — Jacksonville, Florida, United States
• Orlando Health, Inc — Orlando, Florida, United States
• Winship Cancer Institute — Atlanta, Georgia, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Karmanos Cancer Institute — Detroit, Michigan, United States
• University Of New Mexico Cancer Center — Albuquerque, New Mexico, United States
• Mount Sinai School Of Medicine — New York, New York, United States
• Levine Cancer Institute — Charlotte, North Carolina, United States
• Duke University Hospital — Durham, North Carolina, United States
• Dumc — Durham, North Carolina, United States
• University Hospitals Of Cleveland — Cleveland, Ohio, United States
• University Hospitals — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.